A Multicenter Study of SBC-102 (Sebelipase Alfa) in Patients With Lysosomal Acid Lipase Deficiency/ ARISE (Acid Lipase Replacement Investigating Safety and Efficacy)

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Alexion Pharmaceuticals
ClinicalTrials.gov Identifier:
First received: December 17, 2012
Last updated: April 17, 2015
Last verified: April 2015

This Phase 3 study will evaluate the efficacy and safety of 1 mg/kg IV infusions of SBC-102 (sebelipase alfa) administered every other week in patients with late onset lysosomal acid lipase (LAL) deficiency (cholesteryl ester storage disease).

Late onset LAL Deficiency is an underappreciated cause of cirrhosis, liver failure and dyslipidemia. There is currently no standard treatment for LAL Deficiency other than supportive care. Enzyme replacement therapy (ERT) may be a potential new treatment option for LAL Deficiency patients.

Condition Intervention Phase
Cholesterol Ester Storage Disease (CESD)
Lysosomal Acid Lipase Deficiency
Drug: SBC-102 [sebelipase alfa] (1 mg/kg)
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Placebo-Controlled Study of SBC-102 in Patients With Lysosomal Acid Lipase Deficiency

Resource links provided by NLM:

Further study details as provided by Alexion Pharmaceuticals:

Primary Outcome Measures:
  • Proportion of subjects who achieve ALT normalization (i.e., ALT below the age- and gender-specific upper limit of normal provided by the central laboratory performing the assay) relative to placebo [ Time Frame: 20 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Relative change in LDL cholesterol [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • Relative change in non-HDL cholesterol [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • Proportion of subjects with an abnormal baseline AST (i.e., >ULN) who achieve normalization of AST, based on age- and gender-specific normal ranges provided by the central laboratory performing this assay [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • Relative change in triglycerides [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • Relative change in HDL cholesterol [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • In the subset of subjects where performed, relative change in liver fat content [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • In the subset of subjects where performed, proportion of subjects who show improvement in liver histopathology [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • In the subset of subjects where performed, relative change in liver volume [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • Proportion of subjects who achieve ALT normalization (i.e., ALT below the age- and gender-specific upper limit of normal provided by the central laboratory performing the assay) [ Time Frame: 52 weeks and 78 weeks ] [ Designated as safety issue: No ]
  • Incidence of Adverse Events, Serious Adverse Events, and Infusion Related Reactions [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: Yes ]
  • Characterization of Anti-Drug Antibodies (ADAs), including seroconversion rate, time to seroconversion, ADA titer by time point, peak ADA titer, time to peak ADA titer, and tolerization [ Time Frame: 20 weeks, 52 weeks and 78 weeks ] [ Designated as safety issue: Yes ]
  • Peak Plasma Concentration (Cmax) of sebelipase alfa [ Time Frame: Week 0, 22 weeks and 52 ] [ Designated as safety issue: No ]
  • Time to maximum observed concentration (Tmax) of sebelipase alfa [ Time Frame: Week 0, 22 weeks and 52 weeks ] [ Designated as safety issue: No ]
  • Area under the plasma concentration versus time curve (AUC) of sebelipase alfa [ Time Frame: Week 0, 22 weeks and 52 weeks ] [ Designated as safety issue: No ]
  • Terminal elimination half-life (t1/2) of sebelipase alfa [ Time Frame: Week 0, 22 weeks and 52 weeks ] [ Designated as safety issue: No ]
  • Clearance (CL) of sebelipase alfa [ Time Frame: Week 0, 22 weeks and 52 weeks ] [ Designated as safety issue: No ]
  • Volume of distribution (Vd) of sebelipase alfa [ Time Frame: Week 0, 22 weeks and 52 weeks ] [ Designated as safety issue: No ]

Enrollment: 66
Study Start Date: January 2013
Estimated Study Completion Date: October 2015
Primary Completion Date: July 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SBC-102 [sebelipase alfa]
Every other week IV infusions of SBC-102
Drug: SBC-102 [sebelipase alfa] (1 mg/kg)
Placebo Comparator: Placebo
Every other week infusions of placebo
Drug: Placebo

Detailed Description:

Lysosomal Acid Lipase Deficiency (LALD) is a genetic disease which is characterized by abnormal lipid accumulation in many parts of the body due to a marked decrease in activity of the enzyme lysosomal acid lipase (LAL). Although a single disease, LALD presents with two major forms: early onset and late onset. Early onset LALD, also known as Wolman Disease, is characterized by severe malabsorption, growth failure, and hepatic failure and is usually fatal within the first year of life.

The late onset form of the disease, also known as Cholesteryl Ester Storage Disease (CESD), occurs in both children and adults and is an under-appreciated cause of fatty liver with prominent microvesicular steatosis and cirrhosis. Although the natural history of the disease has not been well studied, serious liver complications are frequently described including early death and liver transplantation. Other complications includes premature atherosclerosis (hardening of arteries) associated with high levels of total cholesterol and low-density lipoprotein (LDL) cholesterol, often called the "bad" cholesterol. The levels of triglycerides can also be high and the levels of high-density lipoprotein (HDL) cholesterol (the "good" cholesterol) are typically low.

Current treatments mainly focus on control of the lipid abnormalities through diet and the use of lipid lowering medications. New treatments are needed for patients with LALD as current treatments only address some aspects of the disease and disease progression to cirrhosis still occurs. In pre-clinical studies and studies in patients with LALD, treatment with SBC-102 (sebelipase alfa) has been shown to produce improvements in markers of liver damage and in the lipid abnormalities. The purpose of this study is to examine the effects of using SBC-102 to treat late onset LALD (CESD) through a placebo-controlled, randomized, double-blinded study in both affected children and adults.


Ages Eligible for Study:   4 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject and/or subject's parent or legal guardian provides informed consent
  • Subject is ≥4 years of age
  • Deficiency of LAL enzyme activity confirmed by dried blood spot (DBS) testing at screening
  • ALT ≥1.5x ULN
  • Female subjects of childbearing potential must not be pregnant or breastfeeding
  • Subjects receiving lipid-lowering therapies must be on a stable dose of the medication
  • Subjects receiving medications for the treatment of non-alcoholic fatty liver disease must be on a stable dose

Exclusion Criteria:

  • Severe hepatic dysfunction (Child-Pugh Class C)
  • Other medical conditions or comorbidities which, in the opinion of the Investigator, would interfere with study compliance or data interpretation
  • Previous hematopoietic or liver transplant procedure
  • Received treatment with high-dose corticosteroids (acute or chronic) within 26 weeks. (Note: Subjects receiving maintenance therapy with low-dose oral, intranasal, topical, or inhaled corticosteroids are considered eligible for the study)
  • Known hypersensitivity to eggs
  • Participated in a study employing an investigational medicinal product within 4 weeks prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01757184

  Hide Study Locations
United States, Arizona
Tucson, Arizona, United States
United States, California
Palo Alto, California, United States
San Francisco, California, United States
United States, Delaware
Wilmington, Delaware, United States
United States, Florida
Miami, Florida, United States
United States, Illinois
Chicago, Illinois, United States
United States, Massachusetts
Boston, Massachusetts, United States
United States, New York
Buffalo, New York, United States
Manhasset, New York, United States
New York, New York, United States
United States, Ohio
Cincinnati, Ohio, United States
United States, Pennsylvania
Philadelphia, Pennsylvania, United States
Córdoba, Córdoba Province, Argentina
Australia, Victoria
Parkville, Victoria, Australia
Brisbane, Australia
Newcastle, Australia
Perth, Australia
Porto Alegre, Rio Grande do Sul, Brazil
Monte Alegre, São Paulo, Brazil
Canada, Nova Scotia
Halifax, Nova Scotia, Canada
Canada, Quebec
Montréal, Quebec, Canada
Zagreb, Croatia
Czech Republic
Olomouc, Czech Republic
Prague, Czech Republic
Paris Cedex 15, France
Vandoeuvre les Nancy, France
Freiburg, Germany
Mainz, Germany
Munich, Germany
Athens, Greece
Jerusalem, Israel
Bergamo, Italy
Genoa, Italy
Padova, Italy
Rome, Italy
Turin, Italy
Tokyo, Japan
Tottori, Japan
Mexico City, Mexico
Krakow, Poland
Warszawa, Poland
Russian Federation
Moscow, Russian Federation
Albacete, Spain
Barcelona, Spain
Elche, Spain
Madrid, Spain
Oviedo, Spain
Ankara, Turkey
Izmir, Turkey
United Kingdom
Edgbaston, Birmingham, United Kingdom
Cambridge, United Kingdom
London, United Kingdom
Plymouth, United Kingdom
Salford, United Kingdom
Sponsors and Collaborators
Alexion Pharmaceuticals
  More Information

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Alexion Pharmaceuticals
ClinicalTrials.gov Identifier: NCT01757184     History of Changes
Other Study ID Numbers: LAL-CL02 
Study First Received: December 17, 2012
Last Updated: April 17, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Alexion Pharmaceuticals:
Enzyme Replacement Therapy (ERT)
Lysosomal Storage Disease
Late Onset Lysosomal Acid Lipase (LAL) Deficiency
Acid cholesteryl ester hydrolase deficiency, type 2
Acid lipase disease
Cholesterol ester hydrolase deficiency
LAL Deficiency
LIPA Deficiency
Wolman disease

Additional relevant MeSH terms:
Cholesterol Ester Storage Disease
Wolman Disease
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lipid Metabolism Disorders
Lipid Metabolism, Inborn Errors
Lysosomal Storage Diseases
Metabolic Diseases
Metabolism, Inborn Errors

ClinicalTrials.gov processed this record on February 04, 2016